Drug Synergism: Mechanisms, Clinical Examples, and Distinction from Additivity

Synergism (synergy) occurs when the combined effect of two or more drugs exceeds the sum of their individual effects (1 + 1 > 2).

Types of Drug Interactions

Interaction	Definition	Equation	Example
Synergism	Combined effect > sum of individual effects	E(A+B) > E(A) + E(B)	Trimethoprim + Sulfamethoxazole (sequential folate blockade)
Additivity	Combined effect = sum	E(A+B) = E(A) + E(B)	Acetaminophen + NSAID (different pathways)
Potentiation	One drug enhances another (which has no effect alone)	E(A+B) > E(A); E(B) = 0	Levodopa + Carbidopa (peripheral decarboxylase inhibition)
Antagonism	Combined effect < one alone	E(A+B) < E(A)	Naloxone reversing morphine

Mechanisms of Synergism

1. Sequential blockade: Inhibit successive steps in a pathway (TMP-SMX).
2. Enhanced penetration: One drug increases other's access (amphotericin B + flucytosine).
3. Resistance suppression: Prevent mutant selection (TB multi-drug regimens).
4. Pharmacokinetic: Inhibit metabolism (ritonavir boosting protease inhibitors).
5. Immunomodulation: Checkpoint inhibitors + chemo/radiation.

Clinical Synergistic Combinations

• Antimicrobials: β-lactam + aminoglycoside (enterococcus); TMP-SMX; TB quadruple therapy.
• Oncology: Cisplatin + gemcitabine; immunotherapy doublets (ipilimumab + nivolumab).
• Cardiology: ACEi + ARNI (sacubitril/valsartan) — not combined but sequential.
• Anesthesia: Opioid + hypnotic + muscle relaxant (balanced anesthesia).

Benefits and Risks

• Benefits: Lower doses → reduced toxicity; overcome resistance; broader spectrum.
• Risks: Unexpected toxicity; complex PK/PD; cost; adherence burden.

Assessment Methods

• Isobologram analysis, Combination Index (Chou-Talalay), Bliss independence model.
• Clinical: Superiority trials of combination vs. monotherapy.